Effect of Hyperglycemia on Microvascular Perfusion in Healthy Adults
Status: | Recruiting |
---|---|
Conditions: | Endocrine, Diabetes |
Therapuetic Areas: | Endocrinology |
Healthy: | No |
Age Range: | 18 - 35 |
Updated: | 5/11/2018 |
Start Date: | November 15, 2017 |
End Date: | December 2022 |
Contact: | Eugene J. Barrett, MD PhD |
Email: | ejb8x@virginia.edu |
Phone: | 434-924-1263 |
The investigators are studying the effects of Hyperglycemia on vascular function and insulin
sensitivity on healthy adults
sensitivity on healthy adults
The investigators will study 22 healthy subjects (18-35 yrs) four times as follows:
1. Saline + Octreotide + euglycemia;
2. Octreotide + hyperglycemia;
3. Octreotide + hyperglycemia + insulin clamp and
4. Octreotide + Euglycemia + insulin clamp.
The sequence of admissions will be assigned randomly. The investigators will assess function
in conduit (pulse wave velocity-PWV, augmentation index-AI and flow-mediated dilation-FMD),
resistance (post-ischemic flow velocity-PIFV) and heart and skeletal muscle microvascular
(contrast enhanced ultrasound-CEU) vessels.
This work will:
a) identify whether vascular stiffness and indices of NO action are impaired throughout the
arterial tree with hyperglycemia.
1. Saline + Octreotide + euglycemia;
2. Octreotide + hyperglycemia;
3. Octreotide + hyperglycemia + insulin clamp and
4. Octreotide + Euglycemia + insulin clamp.
The sequence of admissions will be assigned randomly. The investigators will assess function
in conduit (pulse wave velocity-PWV, augmentation index-AI and flow-mediated dilation-FMD),
resistance (post-ischemic flow velocity-PIFV) and heart and skeletal muscle microvascular
(contrast enhanced ultrasound-CEU) vessels.
This work will:
a) identify whether vascular stiffness and indices of NO action are impaired throughout the
arterial tree with hyperglycemia.
Inclusion Criteria:
- Healthy with no chronic illness
- Age 18-35
- Normal BMI (18-25)
- Normal screening labs or no clinically significant values
Exclusion Criteria:
- First degree relative with Type 2 Diabetes
- Smoking presently or in the past 6 months
- Medications that affect the vasculature
- Overweight or other indications of insulin resistance
- Elevated LDL cholesterol > 160
- Elevated BP > 140/90
- History of congestive heart failure, ischemic heart disease, severe pulmonary disease,
liver or kidney disease, bleeding disorders
- Any vascular disease such as myocardial infarction, stroke, peripheral vascular
disease
- Presence of an intracardiac or intrapulmonary shunt (we will screen for this by
auscultation during the physical exam by PI).
- Pregnant or breastfeeding.
- Known hypersensitivity to perflutren (contained in Definity)
We found this trial at
1
site
Charlottesville, Virginia 22903
(434) 924-0311
Principal Investigator: Eugene J. Barrett, MD PhD
Phone: 434-924-1263
University of Virginia The University of Virginia is distinctive among institutions of higher education. Founded...
Click here to add this to my saved trials